Cutanea Life Sciences, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Wayne PA United States (2005)
Status: Acquired by Biofrontera Bioscience GmbH (2019)

Organization Overview

First Clinical Trial
2013
NCT01784133
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CUTANEA | Cutanea Life Sciences, Inc.

Active Ingredients

Marketed Drugs (1)

erythromycin (ilosone) (2000)

Drugs in Phase 3 Trials (2)

furosemide (lasix) (6 trials)

omiganan (13 trials)

Drugs in Phase 2 Trials (3)

digoxin (lanoxin) (4 trials)

ketoconazole (nizoral) (1 trial)

pefcalcitol (1 trial)

Drugs in Phase 1 Trials (1)

imiquimod (aldara) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 2)

Carcinoma in Situ (Phase 2)

Condylomata Acuminata (Phase 2)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Dermatitis, Seborrheic (Phase 2)

Eczema (Phase 2)

Keratosis (Phase 2)

Keratosis, Actinic (Phase 2)

Neoplasms (Phase 2)

Psoriasis (Phase 2)

Rosacea (Phase 3)

Warts (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 20
  • # of Trial APIs: 6